Multispecific binding molecules having specificity to dystroglycan and laminin-2

US11254737B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Christian Beil · Frankfurt am Main, DE
• William Brondyk · Mansfield, US
• Yangde Chen · Wellesley, US
• Seng H. Cheng · Wellesley, US
• Timothy D. Connors · Hopkinton, US
• Catherine Devaud · Paris, FR
• Dietmar Hoffmann · Ashland, US
• Christian Lange · Frankfurt am Main, DE
• Maureen Magnay · Westborough, US
• Tristan Magnay · Westborough, US
• Catherine Prades · Thiais, FR
• Ercole Rao · Frankfurt am Main, DE
• Leila Sevigny · Westborough, US
• Ronnie Wei · Weston, US
• Hongmei Zhao · Southborough, US
• Yunxiang Zhu · Wayland, US

Key dates

• Filing date: Mar 13, 2020
• Grant date: Feb 22, 2022
• Expiry date: Apr 3, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.